Results 151 to 160 of about 1,914,121 (297)

Thyroid hormone receptor can modulate retinoic acid-mediated axis formation in frog embryogenesis.

, 1993
Thyroid hormone receptor acts as a hormone-dependent transcriptional transactivator and as a transcriptional repressor in the absence of thyroid hormone.
Eisenman, R N, Banker, D E
core  

Tolerability of Adjuvant Nivolumab in Esophageal or Gastroesophageal Junction Cancer: A Real‐World Study

International Journal of Cancer, EarlyView.
ABSTRACT Adjuvant nivolumab is approved for esophageal or gastroesophageal junction cancer after neoadjuvant chemoradiotherapy and resection. In the CheckMate‐577 trial, Grade 3–5 nivolumab‐related adverse events (AEs) occurred in 5% of patients, with early discontinuation due to toxicity in 9%. However, real‐world data on immunotherapy‐related adverse
Michelle Koops van ’t Jagt, Anniek Strijdhorst, Tamara Jessica Huizer, Esther Albertien Kleibeuker, Sarah Derks, Bianca Mostert, Hanneke van Laarhoven, Jacco Juri de Haan   +7 more
wiley   +1 more source

The human THRB thyroid hormone receptor gene and the puzzle of retinal disease phenotypes. [PDF]

Dev Biol
Forrest D, Ng L, Cho YW, Liu Y, Liu H.
europepmc   +1 more source

Impact of Single‐Cell RNA Reference Selection for the Deconvolution of Breast Cancer Spatial Transcriptomics Datasets

International Journal of Cancer, EarlyView.
ABSTRACT Spot‐based spatial transcriptomics (ST) allows for unbiased gene expression analysis within tissue architecture, overcoming the limitations of single‐cell RNA sequencing (scRNA‐seq) by preserving spatial context. However, the high spatial resolution in ST leads to cellular heterogeneity within spots, requiring computational deconvolution to ...
Stefan Altendorfer, Scott J. Walker, Carsten O. Daub   +2 more
wiley   +1 more source

Patient‐Reported Outcomes with Selpercatinib Treatment Among Patients with RET‐Mutant Medullary Thyroid Cancer in the Phase I/II LIBRETTO‐001 Trial

The Oncologist, EarlyView., 2021
Abstract Background Medullary thyroid cancer (MTC) standard of care includes multikinase inhibitors (MKIs), which can exacerbate disease‐related diarrhea, primarily because of non‐RET kinase inhibition. We report diarrhea and other patient‐reported outcomes (PROs) with selpercatinib, a highly selective RET inhibitor, among patients with RET‐mutant MTC ...
Lori J. Wirth, Bruce Robinson, Valentina Boni, Daniel S.W. Tan, Caroline McCoach, Erminia Massarelli, Lisa M. Hess, Min‐Hua Jen, Jennifer Kherani, Elizabeth Olek, Vivek Subbiah   +10 more
wiley   +1 more source

Targeting Nuclear Import of Thyroid Hormone Receptor Alpha with Natural Polyphenols: Potential Mechanism for Lipolysis in Metabolic Dysfunction-Associated Steatotic Liver Disease. [PDF]

Curr Issues Mol Biol
Konstantinou EK, Panagiotopoulos AA, Dimitriou M, Castanas E.   +3 more
europepmc   +1 more source

Hormone binding to the thyroid hormone receptor [PDF]

Acta Crystallographica Section A Foundations of Crystallography, 1996
R. Fletterick, R. Wagner, J. Baxter, A. Shiau, J. Apriletti   +4 more
openaire   +1 more source

Incidence and Predictors of Immune‐Related Hypothyroidism Under Pembrolizumab Across Gynecologic Malignancies and Melanoma: A Real‐World Cohort Study

International Journal of Cancer, EarlyView.
ABSTRACT Immune checkpoint inhibitors (ICIs) frequently cause thyroid immune‐related adverse events (irAEs). Permanent hypothyroidism, the clinically most relevant phenotype, requires lifelong hormone replacement. We investigated its incidence, course, risk factors, and prognostic relevance under pembrolizumab.
Freya Koffka, Johann Kornowski, Elena Laakmann, Barbara Schmalfeldt, Tim Zell, Glenn Geidel, Christoffer Gebhardt, Pia Roser, Volkmar Müller, Julian Kött   +9 more
wiley   +1 more source

Thyroid hormone acts independently of the thyroid hormone receptor beta in hepatocytes to improve systemic insulin sensitivity. [PDF]

Hepatol Commun
van der Spek AH, Ritter MJ, Amano I, de Oliveira LS, Kaserman JE, Cespedes IS, Vierling T, Wilson AA, Hollenberg AN.   +8 more
europepmc   +1 more source

Effects of Concomitant Medications on Clinical and Immunological Outcomes of Cancer Patients Treated With Oncolytic Adenoviruses

International Journal of Cancer, EarlyView.
ABSTRACT Medication taken for other reasons than for the treatment of malignant disease, termed concomitant medication, is known to affect outcomes when used with immune checkpoint inhibitor therapy and other oncological drugs. However, no research in humans has addressed the relationship between concomitant medications and efficacy of oncolytic ...
Santeri A. Pakola, Tatiana V. Kudling, Nea Ojala, James H. A. Clubb, Victor Arias, Elise Jirovec, Mirte van der Heijden, Arianna Eleuteri, Lyna Haybout, Susanna Grönberg‐Vähä‐Koskela, Katriina Jalkanen, Tuomo Alanko, Matthew S. Block, Inge Marie Svane, Anna Kanerva, Otto Hemminki, Dafne C. A. Quixabeira, Claudia Kistler, Suvi Sorsa, Victor Cervera‐Carrascon, Akseli Hemminki   +20 more
wiley   +1 more source